Cover Image
市場調查報告書

研究及開發藥劑中誘導性多功能幹細胞 (iPS細胞) 的利用:2015年

Induced Pluripotent Stem Cells In Research & Drug Discovery Trends 2015

出版商 HTStec Ltd 商品編碼 345605
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
研究及開發藥劑中誘導性多功能幹細胞 (iPS細胞) 的利用:2015年 Induced Pluripotent Stem Cells In Research & Drug Discovery Trends 2015
出版日期: 2015年11月25日 內容資訊: 英文
簡介

本報告針對研究及開發藥劑中誘導性多功能幹細胞 (iPS細胞) 的使用概況,基於以歐洲·北美的研究人員為對象所進行的調查結果,提供您受訪者簡介,iPS細胞或iPS細胞衍生細胞的使用概況·利用計劃,iPS細胞的製造與購買,iPS細胞衍生細胞的各種用途,並彙整iPS細胞或iPS細胞衍生細胞領域的應用之關注等相關資訊。

目錄

  • 摘要整理
  • 目錄
  • 調查手法
  • 受訪者的組織·調查的回答
  • 受訪者的公司或出身組織
  • 受訪者的出生地
  • 受訪者的工作職位
  • 現在利用幹細胞的受訪者
  • 調查受訪者數:摘要
  • 各種類型的幹細胞的利用:變化預測
  • 幹細胞衍生細胞相關的工作主要礙
  • 實行公司內部幹細胞差異化Protocols的受訪者
  • 受訪者嘗試幹細胞差異化的細胞家譜
  • 目前業務與iPS細胞或iPS細胞衍生細胞相關的受訪者
  • 可商業性籌資的iPS細胞之利用
  • 商業性籌資的iPS細胞之未來的利用
  • iPS細胞的商業性籌資障礙
  • 調查結果摘要
  • 進行iPS細胞製造相關研究的受訪者
  • 受訪者相關的iPS細胞之工作流程階段
  • iPS細胞製造的消耗品之年度預算
  • iPS細胞製造的消耗品之預算明細實際成果
  • iPS細胞製造用消耗品市場估計
  • iPS細胞製造用消耗品的市場估計:明細
  • 最常使用的iPS細胞製造之消耗品供應商
  • 市售的iPS細胞購買後的受訪者
  • 受訪者購買的市售iPS細胞之主要供應商
  • 市售的iPS細胞之選擇供應商時的最重要因素
  • 市售的iPS細胞之年度購買預算
  • 市售的iPS細胞之購買市場估計
  • 市售的iPS細胞之購買明細
  • 市售的iPS細胞購買市場估計·明細
  • iPS細胞的今後購買的主要影響因素
  • 未上市但已受關注的iPS細胞衍生細胞的類型
  • 受關注的市售iPS細胞衍生細胞的類型
  • 調查結果的摘要
  • 利用了iPS細胞衍生細胞進行毒性研究/安全性實驗的受訪者
  • 利用了各種細胞類型的目前毒性研究/安全性實驗的比例
  • 利用了各種細胞類型的今後毒性研究/安全性實驗的比例
  • 用於毒性研究/安全性實驗的iPS細胞衍生細胞的主要來源
  • 在目前毒性研究/安全性實驗上各種iPS細胞衍生細胞的相對利用
  • 在未來的毒性研究/安全性實驗上各種iPS細胞衍生細胞的相對利用
  • 利用了iPS細胞衍生細胞的毒性研究/安全性化驗所檢查的化合物數 (年度)
  • 利用了iPS細胞衍生細胞的毒性研究/安全性實驗所應用的化驗技術
  • 進行利用了iPS細胞衍生細胞的表現型篩檢化驗的受訪者
  • 利用了各種細胞類型的目前表現型篩檢化驗的比例
  • 表現型篩檢化驗所使用的iPS細胞衍生細胞的主要資源
  • 利用了iPS細胞衍生細胞的表現型化驗篩檢的數據點數
  • 利用了iPS細胞衍生細胞進行疾病建模的受訪者
  • 利用了iPS細胞衍生細胞的疾病建模偏好手法
  • 利用iPS細胞衍生細胞所開發的疾病模式的類型
  • iPS細胞或iPS細胞衍生細胞的其他應用領域的關注
  • 調查結果的摘要等
目錄

This market report summarizes the results of HTStec's industry-wide global web-based benchmarking survey on induced pluripotent stem cells (iPSC) in research and drug discovery carried out in November 2015.

The main objectives of this global benchmarking study were to understand current interest, practices and preferences in carrying out research on stem cells and stem cell-derived cells (particularly iPSC) as well as their utilization in different areas of drug discovery and development.

The study was initiated by HTStec as part of its ongoing tracking of emerging life science markets and in some aspects updates our previous report on the subject (December 2012). The questionnaire was compiled to meet the needs and interests of the stem cell vendor community.

The findings of this research study comprise important feedback for vendors of iPSC and iPSC-related products in order to understand customer needs and focus future product development efforts.

The survey looked at the following aspects of iPSC and/or iPSC-derived cells in research and drug discovery as practiced today (2015) and in some cases as predicted for the future (2017): % of stem cell work that involves different stem cell types; obstacles limiting work with stem cell-derived cells; implementation of stem cell differentiation protocols; cell lineages into which respondents are attempting to differentiate stem cells; work involving iPSC; source of iPSC or iPSC-derived cells; main barriers to sourcing iPSC needs commercially; work involving the generation of iPSC; steps in iPSC workflow undertaken; annual budget for consumables to generate iPSC; budget breakdown into research areas; most purchased from suppliers of consumables used to generate iPSC; purchasing of commercial iPSC; main suppliers of commercial iPSC used; most important factors when choosing a supplier of commercial iPSC; annual budget for purchasing commercial iPSC and breakdown into different cell types; factors that most influence purchasing of iPSC; iPSC-derived cell types of interest that are not commercially available; commercial iPSC-derived cell types of major interest; undertaking toxicology/safety testing using iPSC; % of toxicology/safety testing assays using different cell types; main source of iPSC used in toxicology/safety testing assays; relative use of iPSC-derived cell types in toxicology/safety testing assays; number of compounds tested per year for safety/toxicology applications using iPSC; assay technologies applied to toxicology/safety testing using iPSC; undertaking phenotypic screening assays using iPSC; % of phenotypic screening assays using different cell types; main source of iPSC used in phenotypic screening assays; number of data points (microplate wells) screened per year in phenotypic assays using iPSC; undertaking disease modeling using iPSC; preferred approach to disease modeling; type of disease models being developed; implementation of iPSC-derived cells into existing drug discovery-related assays; drug discovery-related assays which might advantageously be complemented or replaced with iPSC-derived cells; other application areas of iPSC; and likelihood of using any iPSC- or ESC-related services and customization.

The main questionnaire consisted of 43 multi-choice questions. The exact number presented to respondents depended upon their specific use and interests of stem cells. In addition, there were 6 questions related solely to survey demographics.

The survey collected 210 validated responses, of these 64% (135 out of 210) completed the survey.

Survey responses were geographically split: 50% Europe, 31% North America, 8% Asia (excluding Japan), 7% Japan, 2% China; and 2% Rest of World.

Survey respondents were drawn from persons or groups using or interested in using stem cells in life science research and drug discovery applications.

Respondents came from 51 University; 31 Large Pharma; 29 Research Institute; 26 Biotech Company; 25 Contract Research Organization; 13 Medium-Small Pharma; 8 Government Lab; 7 Hospital/Clinic/Medical School; 5 Biopharma; 5 Not-For-Profit Research Center; and 2 Academic Screening Center.

Most survey respondents had a senior job role or position which was in descending order: 26 research scientists; 22 professors/assistant professors; 18 senior scientists/researchers; 18 principal investigators; 11 post-docs; 10 other roles; 9 section/group leaders; 8 directors; 4 graduate/PhD students; 3 lab managers; 3 department heads; and 1 vice president.

Survey results were expressed as an average of all survey respondents. In addition, where appropriate the data was fully reanalyzed after sub-division into the following 5 survey groups: 1) Pharma; 2) Other Screening Labs; 3) University & Research Institute; 4) Europe; and 5) North America.

The majority (80%) of survey respondents were currently using stem cells.

iPSC or iPSC-derived cells were the most investigated stem cell type.

Cost of commercially available cells was rated the main obstacle limiting work with stem cell-derived cells.

34% of survey respondents were currently implementing in house stem cell differentiation protocols.

The cell lineages into which most were attempting to differentiate stem cells were cardiac muscle cells, brain/neuronal/glial cells and hepatocytes.

74% of survey respondents were currently working with iPSC and iPSC-derived cells.

A median of 11-25% of iPSC and 51-75% of iPSC-derived cells are sourced commercially today.

Cost was rated the main barrier to sourcing iPSC or iPSC-derived cell needs commercially.

31% of survey respondents were currently involved in the generation of iPSC or iPSC-derived cells.

The step in the iPSC workflow most undertaken by those generating iPSC or iPSC-derived cells was cell analysis/characterization/validation.

The median annual budget allocated for spending on iPSC and iPSC-derived cell generation consumables today (2015) was $50K-$100K.

A bottom-up model developed around respondent's budget estimated the market for iPSC generation consumables used in drug discovery labs to be around $44M in 2015.

The most purchased from supplier of iPSC generation consumables was Thermo Fisher Scientific.

70% of survey respondents have purchased commercial iPSC or iPSC-derived cells.

The main suppliers of commercial iPSC and iPSC-derived cells were Cellular Dynamics International and Axiogenesis.

Level of validation of cells (including publications) was rated the most important factor in choosing a supplier of commercial iPSC or iPSC-derived cells.

The median annual budget allocated for purchasing commercial iPSC and iPSC-derived cells today (2015) was $10K-$25K.

A bottom-up model developed around respondent's budget estimated the market for commercial iPSC purchased for drug discovery-related assays to be around $45M in 2015. Cardiomyocyte sales make up the biggest proportion of this market.

Level of characterization/validation of cell type was rated the factor that will most influence expected purchasing on iPSC and iPSC-derived cells.

38% of survey respondents were aware of iPSC-derived cell types of interest that are not commercially available, and provided details of the iPSC types lacking.

The commercially available iPSC-derived cell type of most interest was cardiomyocytes (ventricular enriched).

38% of survey respondents were currently undertaking toxicology/safety testing in house using iPSC-derived cells.

The current (2015) breakdown of toxicology/safety testing assays between different cell types was 41% stem cells, 39% cell lines and 20% primary cells.

The main source of iPSC-derived cells used in toxicology/safety testing assays was commercial off-the-shelf cell aliquots.

The iPSC-derived cell type most used in toxicology/safety testing assays today (2015) were cardiomyocytes.

A median of 1-25 compounds were tested per year for toxicology/safety applications using iPSC-derived cells today (2015).

Calcium transients/voltage sensitive dye assays were rated the assay technology survey respondents were most interested in applying to toxicology/safety testing using iPSC-derived cells.

41% of survey respondents were currently undertaking phenotypic screening assays using iPSC-derived cells.

The current (2015) breakdown of phenotypic screening assays between different cell types was 55% stem cells, 24% cell lines and 21% primary cells.

The main source of iPSC-derived cells used in phenotypic screening assays was commercial off-the-shelf cell aliquots.

A median of 1K-5K data points (microplate wells) were screened per year in phenotypic assay applications using iPSC-derived cells today (2015).

35% of survey respondents were undertaking disease modeling in house using iPSC-derived cells.

Selection of donor material (genotype selection) was the preferred approach to disease modeling using iPSC-derived cells.

The most reported disease model being developed using iPSC-derived cells was Parkinson's disease.

Those survey respondents that have implemented iPSC-derived cells into existing drug discovery related assays provided brief details of the assays.

Those survey respondents that could think of drug-discovery related assays which might be advantageously complemented or replaced with iPSC-derived cells provided brief details of the assays.

Interest in other application areas of iPSC or iPSC-derived cells was greatest for investigation of stem cells in regenerative medicine/tissue engineering/cellular therapies and molecular pathway analysis.

Custom generation of specific iPSC or ESC-derived cell types was rated the service or customization involving iPSC or ESC survey respondents were most likely to use over the coming years (up to 2017).

The full report provides the data, details of the breakdown of the responses for each question, its segmentation and the estimates for the future (2017). It also highlights a few interesting differences between the survey groups, particularly Pharma and Other Screening Labs versus University & Research Institute.

Table of Contents

  • Executive Summary
  • Table of Contents
  • Survey Methodology
  • Organisation & Response Of Survey Participants
  • Respondent's Company Or Organisational Origin
  • Respondent's Geographic Origin
  • Respondent's Job Role
  • Respondents Currently Using Stem Cells
  • Summary Of The Number Respondents Answering Questions In Various Aspects Of The Survey
  • % Of Work Done With Different Stem Cell Types Today (2015)
  • % Of Work Done With Different Stem Cell Types In The Future (2017)
  • Anticipated Change In Usage Of Different Stem Cell Type Usage
  • Main Obstacles To Work With Stem Cell-Derived Cells
  • Respondents Implementing In House Stem Cell Differentiation Protocols
  • Cell Lineages Into Which Respondents Are Attempting To Differentiate Stem Cells (1)
  • Cell Lineages Into Which Respondents Are Attempting To Differentiate Stem Cells (2)
  • Respondents Whose Current Work Involves iPSC Or iPSC-Derived Cells
  • % Use Of iPSC Sourced Commercially Today (2015)
  • % Expected Use Of iPSC Sourced Commercially In The Future (2017)
  • Main Barriers To Sourcing iPSC Needs Commercially
  • Summary of Survey Findings (1)
  • Respondents Whose Research Involves The Generation Of iPSC
  • Steps In The iPSC Workflow Undertaken By Respondents
  • Annual Budget For iPSC Generation Consumables
  • Breakdown Of 2015 Budget For iPSC Generation Consumables
  • iPSC Generation Consumables Market Estimate
  • Breakdown Of iPSC Generation Consumables Market Estimate
  • Most Used Suppliers Of iPSC Generation Consumables (1)
  • Most Used Suppliers Of iPSC Generation Consumables (2)
  • Respondents Purchasing Commercial iPSC
  • Main Suppliers Of Commercial iPSC Purchased By Respondents (1)
  • Main Suppliers Of Commercial iPSC Purchased By Respondents (2)
  • Most Important Factors In Choosing A Supplier Of Commercial iPSC
  • Annual Budget For Purchasing Commercial iPSC
  • Commercial iPSC Purchasing Market Estimate
  • Breakdown Of Purchasing On Commercial iPSC
  • Breakdown Of Commercial iPSC Purchasing Market Estimate
  • Factors That Most Influence Expected Future Purchasing Of iPSC
  • iPSC-Derived Cells Types Of Interest That Are Not Commercially Available
  • Commercially Available iPSC-Derived Cell Types Of Interest
  • Summary of Survey Findings (2)
  • Respondents Undertaking Toxicology/Safety Testing Using iPSC-Derived Cells
  • % Of Current Toxicology/Safety Testing Assays Using Different Cell Types
  • % Of Future Toxicology/Safety Testing Assays Using Different Cell Types
  • Main Source Of iPSC-Derived Cells Used In Toxicology/Safety Testing Assays
  • Relative Use Of iPSC-Derived Cell Types In Toxicology/Safety Testing Assays Today
  • Relative Use Of iPSC-Derived Cell Types In Toxicology/Safety Testing Assays Expected In The Future
  • Number Of Compounds Tested Per Year For Toxicology/Safety Assays Using iPSC-Derived Cells
  • Assay Technologies Applied To Toxicology/Safety Testing Using iPSC-Derived Cells
  • Respondents Undertaking Phenotypic Screening Assays Using iPSC-Derived Cells
  • % Of Current Phenotypic Screening Assays Using Different Cell Types
  • Main Source Of iPSC-Derived Cells Used Phenotypic Screening Assays
  • Number Of Data Points Screened Per Year In Phenotypic Assays Using iPSC-Derived Cells
  • Respondents Undertaking Disease Modeling Using iPSC-Derived Cells
  • Preferred Approach To Disease Modeling Using iPSC-Derived Cells
  • Type Of Disease Models Being Developed Using iPSC-Derived Cells
  • Respondents Who Have Implemented iPSC-Derived Cells Into Existing Drug Discovery-Related Assays
  • Respondents Thoughts On Drug Discovery-Related Assays Which Might Be Replaced With iPSC-Derived Cells
  • Interest In Other Application Areas For iPSC Or iPSC-Derived Cells
  • Likelihood Of Using Any iPSC or ESC Related Services Or Customization Over The Coming Years
  • Summary of Survey Findings (3)
Back to Top